Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus‐based study
暂无分享,去创建一个
H. Stein | M. Werner | S. Dirnhofer | M. Kremer | A. Schmitt-Graeff | H. Kreipe | J. Thiele | K. Hussein | H. Kvasnicka | C. Beham‐Schmid | R. Bob | S. Schwarz
[1] H. Kantarjian,et al. Long-Term Effects of Ruxolitinib on Bone Marrow Morphology in Patients With Myelofibrosis and Comparison to Best Available Therapy , 2014 .
[2] S. Ascani,et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms , 2014, Modern Pathology.
[3] S. Rodig,et al. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms , 2014, Modern Pathology.
[4] M. Ehinger,et al. World Health Organization‐defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations—The Danish experience , 2013, American journal of hematology.
[5] H. Kantarjian,et al. Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy , 2013 .
[6] D. Knowles,et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage , 2013, Modern Pathology.
[7] J. Ben-Ezra,et al. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis , 2013, Cancer.
[8] G. Garcia-Manero,et al. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes , 2013, Annals of Hematology.
[9] S. Bosari,et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis , 2012, Modern Pathology.
[10] M. Cazzola,et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.
[11] T. Barbui,et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. , 2012, Blood.
[12] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[13] Xingmin Feng,et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents , 2011, British journal of haematology.
[14] R. Hoffman,et al. Clinical and laboratory features of myelofibrosis and limitations of current therapies. , 2011, Clinical advances in hematology & oncology : H&O.
[15] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[16] M. Cazzola,et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] U. Gianelli,et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. , 2008, Blood.
[18] A. Ganser,et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes , 2008, Leukemia.
[19] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[20] B. Bain,et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres , 2007, British journal of haematology.
[21] N. Kröger,et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. , 2007, Experimental hematology.
[22] J. Thiele,et al. Classification of Ph-Negative Chronic Myeloproliferative Disorders – Morphology as the Yardstick of Classification , 2007, Pathobiology.
[23] J. Thiele,et al. Myelofibrosis – What’s in a Name? , 2007, Pathobiology.
[24] H. Deeg,et al. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] H. Deeg,et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.
[26] J. Vardiman,et al. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. , 2006, Best practice & research. Clinical haematology.
[27] J. Thiele,et al. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. , 2006, Seminars in thrombosis and hemostasis.
[28] J. Thiele,et al. Grade of bone marrow fibrosis is associated with relevant hematological findings—a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis , 2006, Annals of Hematology.
[29] H. Kreipe,et al. Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre‐staining processing of bone marrow biopsies , 2006, Histopathology.
[30] J. Thiele,et al. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach. , 2005, Seminars in hematology.
[31] J. Thiele,et al. Hematopathologic findings in chronic idiopathic myelofibrosis. , 2005, Seminars in oncology.
[32] G. Stein,et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. , 2005, Histology and histopathology.
[33] M. Weiss,et al. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages , 2003, Annals of Hematology.
[34] V. Diehl,et al. Dynamics of Fibrosis in Chronic Idiopathic (Primary) Myelofibrosis During Therapy: A follow-up Study on 309 Patients , 2003, Leukemia & lymphoma.
[35] G. Barosi. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Fischer,et al. Prognostic factors in idiopathic (Primary) osteomyelofibrosis , 1997, Cancer.
[37] A. Manoharan,et al. The Reticulin Content of Bone Marrow in Acute Leukaemia in Adults , 1979, British journal of haematology.
[38] J. Fleiss,et al. Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.
[39] H. Puchtler,et al. Silver impregnation methods for reticulum fibers and reticulin: A re-investigation of their origins and specifity , 1978, Histochemistry.
[40] H. B. Marsden,et al. Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood. , 1978, Journal of clinical pathology.
[41] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .
[42] D. Bauermeister. Quantitation of bone marrow reticulin--a normal range. , 1971, American journal of clinical pathology.
[43] G. Gomori. The effect of certain factors on the results of silver impregnation for reticulum fibers. , 1939, The American journal of pathology.
[44] G. Gömöri. Silver Impregnation of Reticulum in Paraffin Sections. , 1937, The American journal of pathology.
[45] J. Gordon,et al. Further observations on the general bactericidal action of normal serum , 1936 .
[46] H. Gordon,et al. A Simple Method for the Silver Impregnation of Reticulum. , 1936, The American journal of pathology.
[47] S. Verstovsek,et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems , 2014, Modern Pathology.
[48] J. Bussel,et al. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities , 2012, Modern Pathology.
[49] A. Tefferi,et al. Continuing medical education activity in American Journal of Hematology , 2011 .
[50] Peter J Campbell,et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.
[51] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.
[52] V. Diehl,et al. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. , 2004, Histology and histopathology.
[53] H. Kreipe,et al. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. , 2003, American journal of clinical pathology.
[54] J. Fleiss. Measuring nominal scale agreement among many raters. , 1971 .